Research Analysts’ Recent Ratings Updates for Beta Bionics (BBNX)

A number of research firms have changed their ratings and price targets for Beta Bionics (NASDAQ: BBNX):

• 4/22/2026 – Beta Bionics had its price target lowered by Leerink Partners from $25.00 to $24.00. They now have an “outperform” rating on the stock.
• 4/22/2026 – Beta Bionics had its price target lowered by Stifel Nicolaus from $22.00 to $20.00. They now have a “buy” rating on the stock.
• 4/21/2026 – Beta Bionics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 4/15/2026 – Beta Bionics had its price target lowered by Truist Financial Corporation from $25.00 to $18.00. They now have a “buy” rating on the stock.
• 4/9/2026 – Beta Bionics had its price target lowered by The Goldman Sachs Group, Inc. from $23.00 to $20.00. They now have a “buy” rating on the stock.
• 3/29/2026 – Beta Bionics was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/27/2026 – Beta Bionics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/21/2026 – Beta Bionics was upgraded by Wall Street Zen from “sell” to “hold”.

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.